Compare MINISO Group Holding Ltd (MNSO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Recursion Pharmaceuticals Inc — how do they compare? MINISO Group Holding Ltd trades at $9.2 (market cap $2.65B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: MINISO Group Holding Ltd is the larger of the two by market cap, and MINISO Group Holding Ltd pays a 7.34% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MINISO Group Holding Ltd for 24 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MNSO | RXRX | |
|---|---|---|
Market Cap | $2.65B | $2.14B |
Volume | 747,763 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.75 | $6.79 |
52-Week Low | $8.60 | $2.84 |
Typical Hold Time | 24 Days | 22 Days |
Enterprise Value | $3.52B | $1.66B |
Dividend Yield | 7.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, missing estimates in three of the last four quarters but beating in Q1 2026. Revenue grew to $21.44 billion in 2025, with a net income margin of 5.35%. Analyst sentiment is mixed with a 60% buy rating, while recent news highlights CFO share purchases and a 52-week low.
The outlook for MNSO hinges on improving earnings consistency and margin stabilization. Investment opportunities include attractive valuation multiples like a P/E of 14.55 and P/S of 0.78, but risks involve volatile earnings, overseas margin pressures, and competitive retail dynamics. The stock's recent decline to near 52-week lows may present a value entry if operational improvements materialize.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
